Whether our nation’s foreign policy is grounded in America First or American exceptionalism, improving global health should be a top policy priority of the United States. The recent hantavirus outbreak and evolving Ebola crisis serve as a reminder to Congress that the well-being of Americans is tied to the well-being of people around the globe.

Two of us, as former U.S. senators, were fortunate to play leading roles in the launch of PEPFAR, the President’s Emergency Plan for AIDS Relief, in 2003. Our research at the Bipartisan Policy Center demonstrated that beyond saving 26 million lives and preventing millions of HIV infections, PEPFAR contributed to a positive opinion of the U.S., better socioeconomic indices, and reduced political instability in target countries compared with non-PEPFAR countries. We termed this effect “strategic health diplomacy” — the idea that by addressing global health, America advances its own national strategic interests.

Read the rest…

​Read More

Cost cutting is just one factor driving biopharmas to whittle away at their workforces. An analyst discusses more common reasons layoffs occur and which employees are most at risk.​ ​Read More

Biopharmas that announced Series B financing this year and are looking for employees as they grow include two companies that received $100 million or more. One has partnerships with three Big Pharmas.